Skip to content

Observation on the safety and efficacy of laser combined with tranexamic acid extract in the treatment of dark circles under the eyes

Observation on the safety and efficacy of laser combined with tranexamic acid extract in the treatment of dark circles under the eyes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095591
Enrollment
Unknown
Registered
2025-01-09
Start date
2025-01-09
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dark circle

Interventions

Test group:Ocular laser treatments were performed on days 0, 28, and 56 of the study, with the following energy selection: 755 nm picosecond laser, honeycomb lens handpiece, energy 0.71 J/cm2, spot 6
Control subjects:Ocular laser treatments were performed on days 0, 28, and 56 of the study, with the following energy selection: 755 nm picosecond laser, honeycomb lens handpiece, energy 0.71 J/cm2, s

Sponsors

The First Affiliated Hospital, the Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age 20-75 years, male or female, with a diagnosis of pigmented dark circles; (2) Fitzpatrick skin typing of Type II to IV; (3) Subjects agreed to participate in this study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnancy or lactation; (2) Those with keloid body; (3) Those who have undergone skin rejuvenation treatments such as intense light, chemical peeling and laser within 6 months; (4) Those who have undergone botulinum toxin A treatment and filler treatment within 6 months; (5) Combined active psoriasis, vitiligo and other people prone to homoeopathic reactions; (6) Those who have combined severe cardiac, hepatic and renal insufficiency, coagulation disorders, platelet disorders and receive anticoagulation therapy; (7) Those with localized skin infections or excessive expectations of treatment; (8) Those with mental illness; (9)Other subjects deemed by the investigator to be unsuitable for participation in this trial.

Design outcomes

Primary

MeasureTime frame
Using VISIA skin detector to measure changes in facial skin values before and after treatment;Using a CK system to measure changes in facial parameters before and after treatment;Using a 3D system to measure changes in facial parameters before and after treatment;

Secondary

MeasureTime frame
Pain level;Patient satisfaction;

Countries

China

Contacts

Public ContactGao Lin

The First Affiliated Hospital, the Air Force Medical University

13903029@qq.com+86 187 2986 0707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026